The number of clinical trials registered has increased dramatically over the past two decades.
In this issue, Khan et al. 3 report the findings of a network meta-analysis of statins, ezetimibe with or without statins, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and placebo in adult patients with hypercholesteremia. Thirty-nine randomized controlled trials with 189,116 patients were included in the analyses. The authors found that PCSK9 inhibitors significantly reduced the risk of major adverse cardiac events (MACEs) (myocardial infarction (MI), stroke and all-cause mortality), compared to statins (OR 0.78, 95% CrI 0.62-0.97), ezetimibe plus statins (OR 0.72; 95% CrI 0.55-0.95) and placebo (OR 0.63; 95% CrI 0.49-0.79). Statins were associated with a significantly reduced risk of all-cause mortality (OR 0.88; 95% CrI 0.83-0.94). The surface under the cumulative ranking curve (SUCRA) metric was used to rank the effectiveness of each treatment and identify the best treatment. In this brief editorial, some points to consider are presented to help aid the interpretation of their, along with other, network meta-analysis.
Despite the ability of a network meta-analysis to generate paired comparisons, the findings from network meta-analyses are often not sufficient enough for clinicians and patients to choose the best treatment and avoid the worst treatment, especially when there is no obvious winner. Although PCSK9 inhibitors showed advantages over other treatments on MACEs in the study by Khan et al., 3 it is unclear whether PCSK9 inhibitors are still the best for other outcomes, including MI, stroke and mortality, and it is unclear which treatment should be the secondary choice after PCSK9 inhibitors. The authors tried to aid the interpretation by using SUCRA summaries of the data.
Methods have been developed to rank the probability of being the best treatment (i.e. treatment A has a 70% probability of being most effective) and order all treatments from the best, second best, and so on. [4] [5] [6] [7] However, treatments being within a range of ranks are, sometimes, equally important, as the best treatment may be too expensive, may not have been approved by regulatory agencies, or may have serious side effects. Instead of ranking the probability of the best treatment, Salanti et al. developed a method to estimate the probability of all possible ranks, from being the best, second best,. . . to the worst, for each treatment. 8 A graphical presentation can be generated to plot the probabilities against all possible ranks (a 'rankogram'). The SUCRA line shows the percentage of effectiveness of each treatment accounting for all possible rankings and uncertainties in treatment effects. SUCRA values range from 1, being the best without uncertainty, to 0, being the worst without uncertainty. In their study, Khan et al. 3 found that PCSK9 inhibitors were ranked the best for MACEs, MI and stroke, 1 Mayo Clinic, Rochester, USA 2 Mayo Clinic, Jacksonville, USA while statins were ranked the best for all-cause mortality. An example of the graphical presentation and SUCRA results can be found in Figure 3 of the study by Khan et al. 3 SUCRA findings can be misleading and should be interpreted with caution. First, SUCRA does not show whether the difference between treatments is clinically meaningful. While one treatment may be rated as the best, the absolute difference between the best treatment and others may be trivial. An analogy to this statement would be to examine the finishing times for world class athletes in the 100 m sprint. While there may be a runner who consistently wins (ranks first), the time differences with those who did not win could be so slight that a human would not be able to discern the difference without a video of direct head to head comparisons. The difference relative to the untrained runner, however, would be readily apparent. Second, SUCRA findings can be very imprecise. Although Khan et al. 3 did not present credible intervals for SUCRA, an empirical study of 58 network metaanalyses found extremely wide 95% CrIs of SUCRA findings (median width 66.7%, interquartile range 37.5-80.0%) and, in 90% of the network metaanalyses, there was no real difference between the best treatment and the second best treatment. 9 Third, ranking of treatments can distract attention from the evidence and issues underlying individual studies, such as risk of bias, validity of methods and quality of evidence. Finally, the inferences from network metaanalysis have limitations. Network meta-analysis breaks randomization of clinical trials. The inference from the findings should be restricted similar to those from observational studies; findings should not be interpreted causally, for example. Network meta-analysis also requires strong assumptions to be valid, including homogeneity (similar studies within each comparison), transitivity (similar patients and interventions within the network) and consistency (no important deviation between reported results from studies and results from network meta-analysis). Some of these assumptions can be very difficult to verify.
In summary, network meta-analysis evaluates all predefined treatments simultaneously and generates pooled point estimates for all head-to-head comparisons. Rankings, such as rankogram and SUCRA, provide an opportunity to determine the best available treatment. However, one must interpret SUCRA with caution as high values may only provide supportive, but not conclusive, evidence for treatment options.
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